Changing the Perspective on Cardiac Amyloidosis: From Missed and Undiagnosed, to Common and Treatable

2.00 CME
2.00 CNE
120 MINS
$0 FEE
Cardiology Activity

Changing the Perspective on Cardiac Amyloidosis: From Missed and Undiagnosed, to Common and Treatable!

Martha Grogan, MD (Co-Chair) 
Assistant Professor of Medicine
Consultant, Division of Cardiovascular Diseases
Director, Cardiac Amyloid Clinic
Mayo Clinic
Rochester, MN

Mathew S. Maurer, MD (Co-Chair)
Professor of Medicine
Arnold and Arlene Goldstein Professor of Cardiology
Director, Clinical Cardiovascular Research Laboratory for the Elderly
Columbia University Medical Center / New York Presbyterian Hospital
New York, NY

Daniel P. Judge, MD
Professor of Medicine
Director, Cardiovascular Genetics
Director, Adult Cardiology Felllowship Program
Medical University of South Carolina
Charleston, SC

Mazen Hanna, MD
Co-Director, Amyloidosis Center
Section of Heart Failure and Cardiac Transplant Medicine
Cleveland Clinic
Cleveland, OH

Jose Nativi-Nicolau, MD, MSCI
Assistant Professor of Medicine
Director, Cardiovascular Medicine Intensive Care Unit
Director, Cardiac Amyloidosis Program
Heart Failure and Transplant Cardiology
University of Utah
Salt Lake City, UT

Ronald M. Witteles, MD
Associate Professor of Medicine, Division of Cardiovascular Medicine
Co-Director, Stanford Amyloid Center
Program Director, Internal Medicine Residency Training Program
Stanford University School of Medicine
Stanford, CA

Patient Panel:
Isabelle Lousada (Moderator)
CEO & President
Amyloidosis Research Consortium
Newton, MA

Dan Lier
Las Vegas, NV

Cecelia Beckwith
Portland, OR

James Maness
Cedar Park, TX

Credit Hours: 2

Program Description:
Cardiac Amyloidosis is a rare systemic disorder characterized by proteins that possess abnormal conformational features leading them to aggregate and infiltrate tissues in the form of amyloid fibrils resulting in damage to the heart and Heart Failure. Non-specific presenting symptoms and failure to recognize early signs of amyloid heart disease often lead to delay in diagnosis of Cardiac Amyloidosis. Timely diagnosis is critical to managing the disease and preventing mortality. Moreover physicians must maintain a high level of suspicion in order to make a timely diagnosis. This program will examine Cardiac Amyloidosis as a whole; while discussing patient identification, along with current and emerging treatment options.

Program Developer/Facilitator:
Heart Failure Society of America

Target Audience:
Heart failure clinicians and cardiologists who care for patients with HF.

Learning Objectives:
Following this activity, participants will be able to:

  • Define amyloidosis, including specific types and their cardiac features.
  • Identify barriers to patient identification and diagnosis.
  • Propose mechanisms to increase awareness of amyloidosis amongst heart failure providers and referring physicians.
  • Outline current treatment options available for patients with the most common form, TTR amyloidosis.
  • Define updated diagnostic testing available, including imaging options.
  • Outline current and emerging treatments available for patients with different types of cardiac amyloidosis.
  • Discuss the issues regarding transplants for patients with cardiac amyloidosis.

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and HFSA has a process in place to resolve any conflict of interest.

Martha Grogan, MD indicated she has nothing to disclose.
Mazen Hanna, MD, indicated he has nothing to disclose.
Daniel P. Judge, MD, indicated he has nothing to disclose.
Mathew S. Maurer indicated the following relationships: 

  • Research grants from: Pfizer, Eidos
  • Speaker honoraria from Alnylam, Akcea 
  • Consultant/Advisory Board for Pfizer, Eidos, Alnylam, Akcea, GSK

Jose Nativi-Nicolau, MD indicated the following relationships:

  • Consultant/Advisory Board for Alnylam

Ronald Witteles, MD indicated he has nothing to disclose.

HFSA staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Accreditation Statement: 
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:
The Heart Failure Society of America designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)
This activity is approved for 1.5 contact hours.
Approval through 09/05/2020; ONA # 21898

Commercial Support Statement:
Supported by independent medical education grants from the Amyloidosis Research Consortium and Pfizer

Certificate Fee:

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Heart Failure Society of America; the Amyloidosis Research Consortium or Pfizer. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recom